0001209191-17-026343.txt : 20170407
0001209191-17-026343.hdr.sgml : 20170407
20170407180555
ACCESSION NUMBER: 0001209191-17-026343
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20170405
FILED AS OF DATE: 20170407
DATE AS OF CHANGE: 20170407
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: NEKTAR THERAPEUTICS
CENTRAL INDEX KEY: 0000906709
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 943134940
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 455 MISSION BAY BOULEVARD SOUTH
CITY: SAN FRANCISCO
STATE: CA
ZIP: 94158
BUSINESS PHONE: 4154825300
MAIL ADDRESS:
STREET 1: 455 MISSION BAY BOULEVARD SOUTH
CITY: SAN FRANCISCO
STATE: CA
ZIP: 94158
FORMER COMPANY:
FORMER CONFORMED NAME: INHALE THERAPEUTIC SYSTEMS INC
DATE OF NAME CHANGE: 19980723
FORMER COMPANY:
FORMER CONFORMED NAME: INHALE THERAPEUTIC SYSTEMS
DATE OF NAME CHANGE: 19940303
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Hora Maninder
CENTRAL INDEX KEY: 0001443159
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-24006
FILM NUMBER: 17751059
MAIL ADDRESS:
STREET 1: PDL BIOPHARMA, INC.
STREET 2: 1400 SEAPORT BOULEVARD
CITY: REDWOOD CITY
STATE: CA
ZIP: 94063
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2017-04-05
0
0000906709
NEKTAR THERAPEUTICS
NKTR
0001443159
Hora Maninder
C/O NEKTAR THERAPEUTICS
455 MISSION BAY BOULEVARD SOUTH
SAN FRANCISCO
CA
94158
0
1
0
0
SVP Pharma Dev & Mfg Ops
Common Stock
2017-04-05
4
M
0
180000
13.70
A
243648
D
Common Stock
2017-04-05
4
S
0
180000
21.70
D
63648
D
Stock Option
13.70
2017-04-05
4
M
0
180000
0.00
D
2014-08-02
2018-08-01
Common Stock
180000
0
D
This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
This number includes 5,500 shares held by the reporting person from the Issuer's ESPP plan. The acquisition of these shares under this plan is exempt under Rule 16b-3(c).
This transaction was executed in multiple trades at prices ranging from $21.07 to $22.18. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer.
Mark A. Wilson, Attorney-in-Fact
2017-04-07